References
- Plosker G L, Figgitt D P. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63: 803–843
- Merchant S H, Amin M B, Viswanatha D S. Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma: emphasis on phenotypic aberrancies for early diagnosis. Am J Clin Pathol 2006; 126: 29–38
- Abruzzo L V, Schmidt K, Weiss L M, Jaffe E S, Medeiros L J, Sander C A. Raffeld M. B-cell lymphoma after angioimmunoblastic lymphadenopathy: a case with oligoclonal gene rearrangements associated with Epstein-Barr virus. Blood 1993; 82: 241–246
- Viraben R, Brousset P, Lamant L. Cutaneous B-cell lymphoma associated with angioimmunoblastic lymphadenopathy. J Am Acad Dermatol 1998; 38: 992–994
- Feller A C, Griesser H, Schilling C V, Wacker H H, Dallenbach F, Bartels H, et al. Clonal rearrangement patterns correlate with immunophenotype and clinical parameters in patients with angioimmunoblastic lymphadenopathy. Am J Pathol 1988; 133: 549–556
- Lome-Maldonado C, Canioni D, Hermine O, Delabesse E, Damotte D, Raffoux E, et al. Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells associated with Epstein-Barr virus infection. A different subtype of AILD-TL? Leukemia 2002; 16: 2134–2141
- Shinohara A, Asai T, Izutsu K, Ota Y, Takeuchi K, Hangaishi A, et al. Durable remission after the administration of rituximab for EBV-negative, diffuse large B-cell lymphoma following autologous peripheral blood stem cell transplantation for angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 2007; 48: 418–420
- Park S, Noguera M E, Briere J, Feuillard J, Cayuela J M, Sigaux F, et al. Successful rituximab treatment of an EBV-related lymphoproliferative disease arising after autologous transplantation for angioimmunoblastic T-cell lymphoma. Hematol J 2002; 3: 317–320
- Jenkins D, DiFrancesco L, Chaudhry A, Morris D, Glück S, Jones A, et al. Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipient. Bone Marrow Transplant 2002; 30: 321–326
- Tetreault S, Abler S L, Robbins B, Saven A. Peripheral T-cell lymphoma after anti-CD20 antibody therapy. J Clin Oncol 1998; 16: 1635–1637
- Dorfman D M, Brown J A, Shahsafaei A, Freeman G J. Programmed death-1 (PD-1) is a marker of germinal center-associated T-cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2006; 30: 802–810